New Onset Epilepsy — United States (Geriatric population)
In patients aged ≥60 years with new-onset focal epilepsy or unclassified GTC seizures
LTG use should be considered to decrease seizure frequency.
GBP use may be considered to decrease seizure frequency.
In patients aged ≥60 years with new-onset focal epilepsy
LTG should be considered to decrease seizure frequency.
Gabapentin (GBP) may be considered to decrease seizure frequency.
In patients aged ≥60 years
Drug discontinuation is less frequent among patients randomized to LTG (≤150 mg/d) than to GBP (≤1,500 mg/d) or CBZ-IR (≤600 mg/d) because of better LTG tolerability.
In patients aged ≥60 years using GBP
Clinicians should monitor for higher occurrence of weight gain and water retention compared to LTG or CBZ.
In patients aged ≥60 years using CBZ
Clinicians should monitor for higher occurrence of rash compared to LTG, and hyponatremia compared to GBP.
In treating focal epilepsy among patients ≥65 years
Seizure-free rates (52% for LTG vs 57% for CBZ-CR) and AE occurrence leading to withdrawal (14% for LTG vs 25% for CBZ-CR) do not differ significantly between LTG (100–500 mg/d) and CBZ-CR (400–2,000 mg/d).
Related Clinical Tools
